| Literature DB >> 30209392 |
Thomas B Alexander1,2, Zhaohui Gu3, Ilaria Iacobucci3, Kirsten Dickerson3, John K Choi3, Beisi Xu4, Debbie Payne-Turner3, Hiroki Yoshihara3, Mignon L Loh5, John Horan6, Barbara Buldini7, Giuseppe Basso7, Sarah Elitzur8, Valerie de Haas9, C Michel Zwaan9,10, Allen Yeoh11, Dirk Reinhardt12, Daisuke Tomizawa13, Nobutaka Kiyokawa14, Tim Lammens15, Barbara De Moerloose15, Daniel Catchpoole16, Hiroki Hori17, Anthony Moorman18, Andrew S Moore19, Ondrej Hrusak20, Soheil Meshinchi21,22, Etan Orgel23, Meenakshi Devidas24, Michael Borowitz25, Brent Wood26, Nyla A Heerema27, Andrew Carrol28, Yung-Li Yang29, Malcolm A Smith30, Tanja M Davidsen31, Leandro C Hermida32, Patee Gesuwan32, Marco A Marra33, Yussanne Ma33, Andrew J Mungall33, Richard A Moore33, Steven J M Jones33, Marcus Valentine34, Laura J Janke3, Jeffrey E Rubnitz1, Ching-Hon Pui1, Liang Ding4, Yu Liu4, Jinghui Zhang4, Kim E Nichols1, James R Downing3, Xueyuan Cao35, Lei Shi35, Stanley Pounds35, Scott Newman4, Deqing Pei35, Jaime M Guidry Auvil32, Daniela S Gerhard32, Stephen P Hunger36, Hiroto Inaba37, Charles G Mullighan38.
Abstract
Mixed phenotype acute leukaemia (MPAL) is a high-risk subtype of leukaemia with myeloid and lymphoid features, limited genetic characterization, and a lack of consensus regarding appropriate therapy. Here we show that the two principal subtypes of MPAL, T/myeloid (T/M) and B/myeloid (B/M), are genetically distinct. Rearrangement of ZNF384 is common in B/M MPAL, and biallelic WT1 alterations are common in T/M MPAL, which shares genomic features with early T-cell precursor acute lymphoblastic leukaemia. We show that the intratumoral immunophenotypic heterogeneity characteristic of MPAL is independent of somatic genetic variation, that founding lesions arise in primitive haematopoietic progenitors, and that individual phenotypic subpopulations can reconstitute the immunophenotypic diversity in vivo. These findings indicate that the cell of origin and founding lesions, rather than an accumulation of distinct genomic alterations, prime tumour cells for lineage promiscuity. Moreover, these findings position MPAL in the spectrum of immature leukaemias and provide a genetically informed framework for future clinical trials of potential treatments for MPAL.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30209392 PMCID: PMC6195459 DOI: 10.1038/s41586-018-0436-0
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962